Earnings Releases·Nov 12, 2026, 4:17 PM ET

ProKidney — Third Quarter 2026 Earnings Summary

Revenue declined to $174,000 for the three months ended September 30, 2026, from $217,000 in the prior year period, while net loss attributable to Class A common stockholders widened to $35.6 million from $16.5 million.
Operating expenses increased significantly, with R&D rising $14.0 million to $40.8 million and G&A increasing $1.2 million to $13.1 million, driven by clinical study, manufacturing, and compensation costs.
Cash, cash equivalents, and marketable securities decreased to $141.9 million as of September 30, 2026, from $181.6 million at the end of the prior quarter, with management stating current funds support operations into mid-2027.
The PROACT 1 Phase 3 study remains on track for full enrollment in Q1 2027 and pivotal eGFR slope topline results in Q2 2027, with the confirmatory composite endpoint readout expected in the second half of 2029.
Patient recruitment was accelerated in mid-2026, increasing the anticipated enrollment to over 500 patients, and eight abstracts were presented at ASN Kidney Week 2026 regarding rilparencel's mechanism and clinical data.